Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) have received an average recommendation of “Moderate Buy” from the twenty brokerages that are covering the company, Marketbeat reports. Seven analysts have rated the stock with a hold recommendation, eleven have given a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $49.94.

Several analysts have recently commented on APLS shares. William Blair assumed coverage on shares of Apellis Pharmaceuticals in a research report on Wednesday, October 16th. They set an “outperform” rating on the stock. Mizuho reduced their target price on Apellis Pharmaceuticals from $39.00 to $38.00 and set a “neutral” rating on the stock in a research report on Thursday, October 24th. Needham & Company LLC lowered their price target on Apellis Pharmaceuticals from $85.00 to $60.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. Bank of America cut their price objective on Apellis Pharmaceuticals from $61.00 to $47.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $25.00 target price on shares of Apellis Pharmaceuticals in a research report on Monday, November 4th.

Apellis Pharmaceuticals Stock Up 3.7 %

NASDAQ APLS opened at $31.91 on Tuesday. The business’s fifty day simple moving average is $28.92 and its 200-day simple moving average is $35.56. The company has a quick ratio of 3.73, a current ratio of 4.36 and a debt-to-equity ratio of 1.91. The firm has a market cap of $3.97 billion, a PE ratio of -15.72 and a beta of 0.87. Apellis Pharmaceuticals has a 52 week low of $24.34 and a 52 week high of $73.80.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.14). The firm had revenue of $196.83 million for the quarter, compared to analyst estimates of $200.00 million. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. Apellis Pharmaceuticals’s revenue for the quarter was up 78.3% on a year-over-year basis. During the same quarter in the previous year, the business posted ($1.17) earnings per share. As a group, equities analysts anticipate that Apellis Pharmaceuticals will post -1.71 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director A. Sinclair Dunlop sold 37,000 shares of the company’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $36.23, for a total transaction of $1,340,510.00. Following the sale, the director now directly owns 100,000 shares in the company, valued at approximately $3,623,000. This represents a 27.01 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 6.80% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Virtu Financial LLC acquired a new stake in shares of Apellis Pharmaceuticals in the 3rd quarter valued at $390,000. Old West Investment Management LLC acquired a new position in shares of Apellis Pharmaceuticals during the third quarter worth $2,953,000. Toronto Dominion Bank increased its holdings in Apellis Pharmaceuticals by 4.2% in the third quarter. Toronto Dominion Bank now owns 25,622 shares of the company’s stock valued at $739,000 after buying an additional 1,022 shares during the last quarter. Geode Capital Management LLC raised its stake in Apellis Pharmaceuticals by 1.3% in the third quarter. Geode Capital Management LLC now owns 1,810,526 shares of the company’s stock valued at $52,229,000 after buying an additional 22,609 shares in the last quarter. Finally, Barclays PLC raised its stake in Apellis Pharmaceuticals by 18.0% in the third quarter. Barclays PLC now owns 255,897 shares of the company’s stock valued at $7,381,000 after buying an additional 39,019 shares in the last quarter. Hedge funds and other institutional investors own 96.29% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).